There's still the GE Healthcare collaboration, but this outcome has drastically changed my outlook of this company. I sold half before and will monitor the GE Healthcare developments, but likely to get out earlier.
So, my gathering is they spent ages previously after finding a 'better' lead and have only realised during human testing that the pharmacodynamics of this iterarion are different. "This is not seen with other i-bodies" - direct quote from their presentation. So, they didn't bother to test this pharmacology 101 aspect for AD-214 until now? Seems amateurish to me.
There's still the GE Healthcare collaboration, but this outcome...
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $14.91M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.9¢ | 2.7¢ | $9.445K | 348.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 510199 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 681148 | 3 |
View Market Depth
| Last trade - 13.13pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.7¢ |
Change
-0.002 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 2.7¢ | 2.7¢ | 2.7¢ | 269805 | ||
| Last updated 13.13pm 03/05/2024 ? | |||||
| 1AD (ASX) Chart |